Apellis Pharmaceuticals (APLS) Announces Results of Phase 3 DERBY and OAKS Studies in Geographic Atrophy, Plans NDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Apellis Pharmaceuticals (APLS) Announces Results of Phase 3 DERBY and OAKS Studies in Geographic Atrophy, Plans NDA

Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

September 9, 2021 4:05 PM EDT

OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 monthsDERBY did not meet the primary endpoint of GA lesion growth, showing a reduction... More